These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37897008)

  • 1. Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong.
    Wang Y; Fekadu G; You JHS
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37897008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Prefusion F Protein-Based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.
    Moghadas SM; Shoukat A; Bawden CE; Langley JM; Singer BH; Fitzpatrick MC; Galvani AP
    medRxiv; 2023 Aug; ():. PubMed ID: 37645896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
    Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
    Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
    Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Herring WL; Zhang Y; Shinde V; Stoddard J; Talbird SE; Rosen B
    Vaccine; 2022 Jan; 40(3):483-493. PubMed ID: 34933763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines.
    Topalidou X; Kalergis AM; Papazisis G
    Pathogens; 2023 Oct; 12(10):. PubMed ID: 37887775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
    You JH; Ming WK; Chan PK
    Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
    Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
    Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
    Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
    BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis.
    Xiong X; Li J; Huang B; Tam T; Hong Y; Chong KC; Huo Z
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease.
    Med Lett Drugs Ther; 2023 Oct; 65(1686):155-156. PubMed ID: 37755690
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory Syncytial Virus Infection: An Update.
    Soni A; Kabra SK; Lodha R
    Indian J Pediatr; 2023 Dec; 90(12):1245-1253. PubMed ID: 37326948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children.
    Wong C; Jiang M; You JH
    PLoS One; 2016; 11(12):e0169030. PubMed ID: 28006012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis.
    Xing N; Cheung WY; Jiang M; You JHS
    Am J Infect Control; 2019 Nov; 47(11):1302-1308. PubMed ID: 31266663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.
    Cheung TH; Cheng SSY; Hsu DC; Wong QW; Pavelyev A; Walia A; Saxena K; Prabhu VS
    Cost Eff Resour Alloc; 2021 Nov; 19(1):75. PubMed ID: 34801050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.
    Leung MK; You JH
    Vaccine; 2016 May; 34(22):2469-76. PubMed ID: 27079928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom.
    Zeevat F; Luttjeboer J; Paulissen JHJ; van der Schans J; Beutels P; Boersma C; Postma MJ;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S102-S109. PubMed ID: 34522947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.